Sertraline in the Treatment of Generalized Social Phobia with Comorbidity

Selective serotonin reuptake inhibitors (SSRIs) including sertraline (Zoloft) have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders. Participants will be randomized to receive either sertraline or placebo for 16 weeks. At the end of the study, you will enter follow-up care with the study doctor.

Organization: 
McMaster University Medical Centre
Principal Investigator: 
Michael Van Ameringen, MD
Eligibility Criteria: 
  • Male or female outpatients 18 years or older with a primary diagnosis of generalized social anxiety disorder as well as at least one another anxiety disorder (as determined by the psychiatrists who conduct our initial screening process).
  • Physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities.
  • Willingness and ability to comply with the requirements of the study protocol.
  • Those taking other psychotrophic medications are excluded.
Contact: 
The MacAnxiety Research Centre, 905-921-7644 or e-mail jasmine@macanxiety.com
Location: 
Hamilton, ON
State: 
Ontario

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Privacy Policy 
© ADAA, 2010-2014